According to the World Health Organisation, up to a half-million people around the world suffer a spinal cord injury each year. Often caused by road traffic crashes, accidents or violence, the loss of motor control or paralysis significantly impacts quality of life and requires years of treatment and care. Spinal cord injury is also associated with lower rates of school enrollment and economic participation, and carries substantial individual and societal costs.
Current methods for spinal cord injury treatment involve cumbersome brain-machine interfaces, with many cables linking the patient and a computer to restore limited motor functions.
In an inspiring example of inclusive design, Sesame Access offers a solution to one of wheelchair-users biggest difficulties when navigating the urban environment. The UK-based company creates invisible wheelchair lifts, concealed within bespoke staircases which transform at the touch of a button.
Using cutting edge engineering technology Sesame Access has installed lifts across Cambridge Universities, Kensington Palace, Tate Britain and Sotheby’s Paris, among other locations. The lift is called by pressing a button, causing the steps of the staircase to retract, revealing a platform for wheelchairs to be elevated to the desired level.
We are here to inspire independence in anyone affected by spinal cord injury and to encourage everyone to get the most from their lives. We work with people of all ages, from young children to the elderly, whatever the motivation or background.
Back Up relies on a vital family of volunteers, mentors and skilled professionals, who provide unrivaled support and enthusiasm for our work and who help us deliver services that rebuild confidence and self-belief.
We help people realize their ambitions and overcome prejudice, creating the opportunity to transform lives.
Acorda Therapeutics said today it won a $2.67 million contract from the U.S. Army Medical Research and Material Command (USAMRMC) to support development of AC105 as a treatment for acute spinal cord injury (SCI).
The contract will help fund a Phase II clinical trial designed primarily to assess the safety and tolerability of AC105 in patients with acute SCI. The company plans to open enrollment for this study in the first half of this year.